This activity was provided by grants from Congressman Jamie Raskin and by the Substance Abuse and Mental Health Services Administration.

About the speaker

Dr. Jeffrey LaPratt is the lead DBT psychologist at Sheppard Pratt, working on the teams at The Retreat by Sheppard Pratt and the Center for Excellence in Psilocybin Research, part of Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics. Dr. LaPratt earned his PsyD in Clinical Psychology from Florida School of Professional Psychology, where his studies focused on forensic and clinical psychology. 

In Dr. LaPratt’s role at Sheppard Pratt, he is responsible for conducting psychological assessments across care settings, and delivering dialectical behavior therapy (DBT) in individual and group settings. He also oversees provision of DBT trainings throughout the Sheppard Pratt system. Prior to joining Sheppard Pratt, Dr. LaPratt served as a psychologist within the California Department of Corrections and Rehabilitation, providing Comprehensive DBT treatment in an inpatient prison hospital setting, as well as psychodiagnostic assessments, violence, and suicide risk evaluations.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services, or off-label uses of product(s) during this presentation.

Jeffrey LaPratt, PsyD, reports that he has no relationships with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. He will be discussing the off-label use of pramipexole for treatment resistant depression in this presentation. 

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Stephanie M. Robinson, MSN, RN, PMH-BC, NPD-BC, NE-BC , Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.